{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+powder+OR+higher+carbohydrate&page=38",
    "query": {
      "intervention": "Placebo powder OR higher carbohydrate",
      "page": 38
    },
    "page_size": 10
  },
  "pagination": {
    "page": 38,
    "page_size": 10,
    "total_count": 2369,
    "total_pages": 237,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+powder+OR+higher+carbohydrate&page=39&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+powder+OR+higher+carbohydrate&page=37&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T00:03:23.069Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05113251",
      "title": "Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Breast Cancer",
        "HER2-positive Early Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Trastuzumab Deruxtecan",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 927,
      "start_date": "2021-10-25",
      "completion_date": "2027-04-30",
      "has_results": true,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-10-17T00:03:23.069Z",
      "location_count": 22,
      "location_summary": "Springdale, Arkansas • Beverly Hills, California • Glendale, California + 19 more",
      "locations": [
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05113251"
    },
    {
      "nct_id": "NCT00436631",
      "title": "Internet Administration of the Modified Atkins Diet for Adults With Intractable Epilepsy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "Dietary management of seizures",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2007-02",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2015-09-02",
      "last_synced_at": "2026-10-17T00:03:23.069Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00436631"
    },
    {
      "nct_id": "NCT00669877",
      "title": "Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Burkitt's Lymphoma",
        "Burkitt'S-like Lymphoma"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 56,
      "start_date": "2002-08",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2018-05-16",
      "last_synced_at": "2026-10-17T00:03:23.069Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00669877"
    },
    {
      "nct_id": "NCT03363373",
      "title": "Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "GM-CSF + Naxitamab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Y-mAbs Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Year and older"
      },
      "enrollment_count": 122,
      "start_date": "2018-04-03",
      "completion_date": "2028-04",
      "has_results": false,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-10-17T00:03:23.069Z",
      "location_count": 2,
      "location_summary": "Indianapolis, Indiana • New York, New York",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03363373"
    },
    {
      "nct_id": "NCT02278705",
      "title": "Primary Care Clinical Practice Elements and Improving Overweight Children's Weight Status",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Overweight",
        "Childhood Obesity"
      ],
      "interventions": [
        {
          "name": "Attention to BMI",
          "type": "OTHER"
        },
        {
          "name": "Attention to high-BMI-related Medical Risk",
          "type": "OTHER"
        },
        {
          "name": "No attention to high BMI or high-BMI-related medical risk",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "6 Years to 12 Years"
      },
      "enrollment_count": 7192,
      "start_date": "2009-01",
      "completion_date": "2015-09",
      "has_results": false,
      "last_update_posted_date": "2020-05-19",
      "last_synced_at": "2026-10-17T00:03:23.069Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02278705"
    },
    {
      "nct_id": "NCT06098001",
      "title": "Bioavailability Study of Hemp Phenolics",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Bioavailability",
        "Metabolites",
        "Excretion"
      ],
      "interventions": [
        {
          "name": "Low dose dietary fiber",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "High dose dietary fiber",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Brightseed",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 10,
      "start_date": "2023-09-15",
      "completion_date": "2023-12",
      "has_results": false,
      "last_update_posted_date": "2023-10-24",
      "last_synced_at": "2026-10-17T00:03:23.069Z",
      "location_count": 1,
      "location_summary": "Addison, Illinois",
      "locations": [
        {
          "city": "Addison",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06098001"
    },
    {
      "nct_id": "NCT07611305",
      "title": "ProGo Menopause Wellbeing Study",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Menopause Related Conditions"
      ],
      "interventions": [
        {
          "name": "Salmon protein hydrolysate (SPH) powder formulated into a tablet format",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Microcrystalline Cellulose",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Hofseth Biocare ASA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 65 Years · Female only"
      },
      "enrollment_count": 100,
      "start_date": "2026-10",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-10-17T00:03:23.069Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07611305"
    },
    {
      "nct_id": "NCT06456541",
      "title": "Infant Formula in Infants and Children With Cow's Milk Allergy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cow's Milk Allergy"
      ],
      "interventions": [
        {
          "name": "Experimental Extensively Hydrolyzed Formula",
          "type": "OTHER"
        },
        {
          "name": "Placebo Extensively Hydrolyzed Formula",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Abbott Nutrition",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "3 Months to 12 Years"
      },
      "enrollment_count": 96,
      "start_date": "2024-10-01",
      "completion_date": "2029-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-10-17T00:03:23.069Z",
      "location_count": 9,
      "location_summary": "Phoenix, Arizona • Aurora, Colorado • Chicago, Illinois + 6 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06456541"
    },
    {
      "nct_id": "NCT01872351",
      "title": "Therapy for Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Fatigue Syndrome"
      ],
      "interventions": [
        {
          "name": "Nutraceuticals",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "20 Years to 70 Years"
      },
      "enrollment_count": 0,
      "start_date": "2011-11",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2016-10-14",
      "last_synced_at": "2026-10-17T00:03:23.069Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01872351"
    },
    {
      "nct_id": "NCT05600686",
      "title": "Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Double-Expressor Lymphoma",
        "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Loncastuximab Tesirine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2023-05-24",
      "completion_date": "2027-12-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-10-17T00:03:23.069Z",
      "location_count": 2,
      "location_summary": "Sacramento, California • San Diego, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05600686"
    }
  ]
}